BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + [14C] BMS-813160 + Placebo + BMS-813160 + BMS-813160
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Accelerated Intimal Hyperplasia
Conditions
Accelerated Intimal Hyperplasia
Trial Timeline
Feb 1, 2010 → Nov 1, 2010
NCT ID
NCT01049165About BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + [14C] BMS-813160 + Placebo + BMS-813160 + BMS-813160
BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + BMS-813160 + [14C] BMS-813160 + Placebo + BMS-813160 + BMS-813160 is a phase 1 stage product being developed by Bristol Myers Squibb for Accelerated Intimal Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT01049165. Target conditions include Accelerated Intimal Hyperplasia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01049165 | Phase 1 | Completed |
Competing Products
4 competing products in Accelerated Intimal Hyperplasia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Blinatumomab + Cytarabine + Methotrexate + Ponatinib | Amgen | Phase 2 | 51 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 51 |
| dasatinib + dasatinib | Bristol Myers Squibb | Phase 3 | 76 |
| Ruxolitinib + Enasidenib | Incyte | Phase 2 | 49 |